Tennessee Enacts HOPE Act, Clearing Path for Ibogaine Clinical Trials

Tennessee has become the latest state to embrace the accelerating movement toward psychedelic medicine, enacting legislation that opens the door for FDA-approved clinical trials of ibogaine. The HOPE Act—short for "Helping Open Pathways to Effective Treatment"—positions Tennessee alongside Texas and Arizona as states actively pursuing research into a compound that advocates say could transform treatment for opioid addiction and post-traumatic stress disorder.

The state-level action follows an executive order signed by President Donald Trump in late April that directed federal agencies to prioritize research into psychedelic therapies, establish a $50 million fund through the Advanced Research Projects Agency for Health (ARPA-H), and create a pathway for FDA priority vouchers for breakthrough treatments. Tennessee lawmakers moved quickly to align state law with this federal momentum, passing the HOPE Act just one week after the White House announcement.

What the HOPE Act Enables

Under the new law, Tennessee universities can now participate in Food and Drug Administration-approved clinical trials of ibogaine, a Schedule I psychedelic derived from the root bark of the iboga plant native to West Africa. The legislation creates a regulatory framework that allows researchers to administer the compound to carefully screened patients under medical supervision.

State Senator Page Walley, a Republican from Savannah who sponsored the bill, framed the legislation as a response to the limitations of existing mental health treatments. "The tools we have just aren't well enough or fast enough," Walley said during the legislative process. The bill garnered bipartisan support, with proponents emphasizing the potential benefits for military veterans struggling with treatment-resistant conditions.

Ibogaine's classification as a Schedule I substance—placing it in the same category as LSD and heroin under federal law—has historically blocked clinical research in the United States. The Tennessee law does not change this federal classification, but it creates state-level authorization that allows institutions to participate in federally sanctioned trials.

The Science Behind Ibogaine

Research into ibogaine's therapeutic potential dates back decades, though rigorous clinical trials have been limited by regulatory barriers. The compound appears to work through multiple mechanisms: it interacts with NMDA receptors and opioid receptors while also promoting neuroplasticity—the brain's ability to form new neural connections.

Bryan Hubbard of Americans for Ibogaine, an advocacy organization that has pushed for expanded research access, describes the compound's potential in striking terms. "Ibogaine has the potential, over the course of perhaps two to three treatments over an individual's lifetime, to physiologically resolve opioid addiction even among those who have been dependent for decades," Hubbard testified before Tennessee lawmakers.

Unlike maintenance medications such as methadone or buprenorphine, which require daily dosing, ibogaine is typically administered in one to three sessions under medical supervision. Proponents argue this approach addresses the neurobiological changes associated with addiction rather than merely managing withdrawal symptoms.

However, the compound carries significant safety concerns. Ibogaine has been associated with cardiac risks, including arrhythmias, and several deaths have been reported in unregulated settings outside the United States. These safety issues underscore why advocates emphasize the importance of clinical trials conducted under FDA oversight with proper cardiac monitoring and medical screening.

Voices from the Community

The Tennessee legislative hearings featured testimony from individuals who have experienced ibogaine treatment firsthand, often traveling internationally to access it in countries where medical use is permitted.

Retired Navy SEAL Alex West told lawmakers that ibogaine treatment saved his life after years of depression and substance abuse linked to combat experiences. "I was struggling. I really was, and something needed to change," West testified. He described being prescribed five different psychotropic medications before seeking ibogaine treatment outside the country.

"Today, I'm six years sober from alcohol and no longer on any psychotropic medication, down from five," West said. His testimony illustrates why veterans' organizations have become prominent advocates for expanded research into psychedelic therapies, arguing that conventional treatments fail too many former service members.

The National Context

Tennessee's entry into ibogaine research reflects a broader shift in how policymakers view psychedelic compounds. What began as isolated municipal efforts—such as Denver's 2019 decriminalization of psilocybin—has evolved into coordinated state and federal action encompassing multiple compounds and therapeutic targets.

The Trump administration's executive order specifically named ibogaine alongside psilocybin and MDMA as compounds warranting accelerated research. It directed the Department of Veterans Affairs to expand access to psychedelic therapies for veterans with PTSD and traumatic brain injury, and instructed the FDA to consider priority review vouchers for breakthrough psychedelic treatments.

Texas established a medical psilocybin program through legislation passed in 2023, with implementation scheduled for late 2026. Arizona has similarly moved to authorize research into psychedelic therapies. The Tennessee law differs in focusing specifically on ibogaine rather than psilocybin, reflecting the compound's particular association with addiction treatment.

No psychedelic drug currently has FDA approval for any medical indication. MDMA-assisted therapy for PTSD received a Complete Response Letter from the FDA in 2024, with the agency requesting additional data. Psilocybin remains in Phase 3 trials for depression. If successful, ibogaine could become the first psychedelic to gain FDA approval, though significant hurdles remain.

What Comes Next

Tennessee officials plan to begin accepting proposals from universities interested in conducting ibogaine trials later this year. The selection process will likely prioritize institutions with existing expertise in addiction medicine and psychiatric research, as well as those with established veterans' health programs.

For people struggling with opioid addiction, the Tennessee legislation represents another potential pathway toward recovery—though one that remains experimental and unproven in rigorous clinical trials. The HOPE Act does not make ibogaine legally available for general use; it merely creates a framework for supervised research participation.

The coming years will determine whether ibogaine lives up to the hopes of its advocates or joins the long list of compounds that showed promise in preliminary studies but failed to demonstrate sufficient safety and efficacy for clinical approval. What distinguishes the current moment is the convergence of federal and state policy creating space for that question to be answered through properly controlled research rather than anecdote and advocacy alone.